The Health Resources and Services Administration should abandon its consideration of a 340B rebate model pilot program ...

Hospitals and clinics told regulators that switching to rebates in the 340B drug discount program would impose costs that would outweigh the program’s benefits.

In February 2026, the Department of Justice filed amicus briefs supporting pharmaceutical manufacturers, asserting that Rhode ...

Hospital and pharma groups have sharpened their spears for the rematch on 340B rebates.  | The administration's second stab ...

AHA urges HRSA to axe 340B model that would cost hospitals over $1 billion annually and increase administrative burdens.

A federal court has struck down a 12-year-old Health Resources and Services Administration policy that restricted how certain 340B hospitals could make initial drug purchases, finding that the agency ...

LYNN– At a recent State House briefing hosted by the Massachusetts Health & Hospital Association, healthcare leaders gathered ...

While it may be hard to believe, there is one issue in Washington that meets the above criteria: fixing the 340B program.

AbbVie is spearheading a new battle in pharma’s long-running fight to reform the federal government’s 340B drug discount ...

Regarding the April 20 editorial “Corporate welfare for hospitals is raising health care costs”: There are many commonsense, ...

The 340B Drug Pricing Program must be reformed to better patient health and disincentivize institutional profit-seeking ...